Valuation

CRSPCRISPR Therapeutics AG

StockNasdaqSwitzerlandHealth careEU retail investors: available

+1.3% today · −17.1% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 7% of the instruments we score

Quality, Stability: among the weakest; priced higher than most peers. No dividend.

CRISPR Therapeutics AG (CRSP) valuation against sector peers: P/B 2.7, free-cash-flow yield −8.5%, P/S 176.3.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricCRSPSector medianvs median
P/E—25.6 · n=26—
P/B2.73.7 · n=4526% below
P/S176.34.7 · n=403,624% above
EV/EBIT—22.5 · n=28—
Free-cash-flow yield−8.5%3.8% · n=39325% below
Dividend yield0.00%0.19% · n=99100% below
Return on equity−25.6%5.2% · n=56591% below
Return on invested capital−26.1%6.5% · n=47502% below
Gross margin—70.2% · n=39—
Net debt / EBITDA—2.08 · n=25—

Value factor: 6 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NVSNovartis AG21.96.618.35.8%2.5%10/10
NOVNNovartis AG21.86.618.35.8%2.8%10/10
AZNAstraZeneca PLC28.15.922.74.1%1.2%5/10
AZNAstraZeneca plc28.05.922.64.1%1.7%7/10
NVONovo Nordisk A/S12.06.310.44.8%4.5%7/10
SNYSanofi13.61.518.46.8%4.3%7/10
SANSanofi SA13.51.518.36.8%4.8%9/10
GSKGSK plc14.25.011.67.9%4.5%9/10
TEVATeva Pharmaceutical Industries Limited99.76.344.02.4%0.0%6/10
ALCAlcon36.01.628.34.9%0.4%4/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 02 Nov 2026